Having trouble accessing articles? Reset your cache.

Zohydro ER hydrocodone bitartrate regulatory update

In February, Zogenix said FDA delayed its decision on an NDA for Zohydro ER hydrocodone bitartrate to manage moderate to severe chronic pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time. FDA did not

Read the full 407 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers